LS22, Inc.
Funding rounds
5 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2022 | $130 M | Issued in a merger or acquisition | $50 to $250 million | equity, options | SEC | |
| Dec 2020 | $90 M | No. 5 | $50 to $250 million | equity, options | SEC | |
| Jan 2018 | $11 M | No. 4 | $10 to $50 million | equity | SEC | |
| Oct 2014 | $53 M | No. 3 | $50 to $250 million | equity | SEC | |
| Apr 2013 | $10 M | No. 2 | $10 to $50 million | equity | SEC | |
| Aug 2012 | $1 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
LS22, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2022).
SEC Form D · Sep 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2022
That is all the official record says: LS22, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
24 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Aisling Capital III LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Aisling Capital Partners III LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Aisling Capital Partners III LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Arch Venture Fund VII LP | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| ARCH Venture Partners VII, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| ARCH Venture Partners VII, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Flagship VentureLabs IV, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Flagship Ventures Fund IV General Partner LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Flagship Ventures Fund IV, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Flagship Ventures Fund IV-Rx, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Nancy A. Simonian | Person | not stated | not stated | Held Series A-2 preferred stock, 10% owner, director (Form 3, 2016) | SEC Form 3 |
| Philip A. Sharp | Person | not stated | not stated | Held Series A-2 preferred stock, 10% owner, director (Form 3, 2016) | SEC Form 3 |
| Polaris Entrepreneurs' Fund VII, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Polaris Management Co. VII, L.L.C. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Polaris Partners VII, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Stephane Bancel | Person | not stated | not stated | Held Series A-2 preferred stock, director (Form 3, 2016) | SEC Form 3 |
| WuXi Healthcare Ventures II, L.P. | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| WuXi PharmTech Healthcare Fund I L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 16 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Conely C. Chee | Executive officer | Sep 2022 |
| David C. Roth | Executive officer | Sep 2022 |
| Eric C. Olson | Executive officer | Sep 2022 |
| Jason C. Haas | Executive officer | Sep 2022 |
| Kristin C. Stephens | Executive officer | Sep 2022 |
| Nancy Simonian | Executive officer | Sep 2022 |
| David Gail Roth | Executive officer | Dec 2020 |
| Eric Gail Olson | Executive officer | Dec 2020 |
| Gerald Gail Quirk | Executive officer | Dec 2020 |
| Jeremy Gail Springhorn | Executive officer | Dec 2020 |
| Joseph Gail Ferra, Jr. | Executive officer | Dec 2020 |
| David A. Roth | Executive officer | Feb 2018 |
| Eric A. Olson | Executive officer | Feb 2018 |
| Gerald A. Quirk | Executive officer | Feb 2018 |
| Jeremy A. Springhorn | Executive officer | Feb 2018 |
| Jorge Conde | Executive officer | Oct 2014 |
| Harry Wilcox III | Executive officer | Apr 2013 |
| Douglas Cole | Executive officer | Aug 2012 |
| Harry W. Wilcox III | Executive officer | Aug 2012 |
| Andrew C. Oh | Director | Sep 2022 |
| Deborah Dunsire | Director | Sep 2022 |
| Mark Alles | Director | Sep 2022 |
| Marsha A. Fanucci | Director | Sep 2022 |
| Nancy Simonian | Director | Sep 2022 |
| Peter Wirth | Director | Sep 2022 |
| Richard A. Young | Director | Sep 2022 |
| Srinivas Akkaraju | Director | Sep 2022 |
| Sue Gail Eckhardt | Director | Sep 2022 |
| Timothy C. Tyson | Director | Sep 2022 |
| Amir Nashat | Director | Dec 2020 |
| Philip Sharp | Director | Dec 2020 |
| Robert Nelsen | Director | Feb 2018 |
| Sanj A. Patel | Director | Feb 2018 |
| Vicki Sato | Director | Feb 2018 |
| Douglas E. Cole | Director | Oct 2014 |
| James E. Bradner | Director | Oct 2014 |
| Philip E. Sharp | Director | Oct 2014 |
| Robert E. Nelsen | Director | Oct 2014 |
| Stephane Bancel | Director | Oct 2014 |
| Vicki E. Sato | Director | Oct 2014 |